Esperion Therapeutics Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Sheldon Koenig

Chief executive officer

US$3.0m

Total compensation

CEO salary percentage	24.3%
CEO tenure	3yrs
CEO ownership	0.09%
Management average tenure	2.3yrs
Board average tenure	2.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Sheldon Koenig's remuneration changed compared to Esperion Therapeutics's earnings?
Date	Total Compensation	Salary	Company Earnings
Mar 31 2024	n/a	n/a	-US$87m
Dec 31 2023	US$3m	US$721k	-US$209m
Sep 30 2023	n/a	n/a	-US$208m
Jun 30 2023	n/a	n/a	-US$222m
Mar 31 2023	n/a	n/a	-US$239m
Dec 31 2022	US$4m	US$683k	-US$234m
Sep 30 2022	n/a	n/a	-US$243m
Jun 30 2022	n/a	n/a	-US$258m
Mar 31 2022	n/a	n/a	-US$235m
Dec 31 2021	US$8m	US$566k	-US$269m
Sep 30 2021	n/a	n/a	-US$308m
Jun 30 2021	n/a	n/a	-US$325m
Mar 31 2021	n/a	n/a	-US$156m
Dec 31 2020	US$508k	US$23k	-US$144m

Compensation vs Market: Sheldon's total compensation ($USD2.97M) is above average for companies of similar size in the German market ($USD997.20K).

Compensation vs Earnings: Sheldon's compensation has been consistent with company performance over the past year.

CEO

Sheldon Koenig (57 yo)

3yrs

Tenure

US$2,968,565

Compensation

Mr. Sheldon L. Koenig has been President, Chief Executive Officer and Director at Esperion Therapeutics, Inc. since May 17, 2021 and had been its Chief Operating Officer since December 15, 2020 until May 1...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Sheldon Koenig	President	3yrs	US$2.97m	0.087% $ 323.6k
JoAnne Foody	Chief Medical Officer	2.9yrs	US$1.42m	0.036% $ 134.1k
Eric Warren	Chief Commercial Officer	2.2yrs	US$1.08m	0.021% $ 79.0k
Benjamin Halladay	Chief Financial Officer	1.5yrs	no data	0.13% $ 480.8k
Glenn Brame	Chief Technical Operations Officer	1.3yrs	no data	no data
Benjamin Looker	General Counsel & Corporate Secretary	2.3yrs	US$1.29m	0.097% $ 362.0k
Tiffany Aldrich	Associate Director of Corporate Communications	no data	no data	no data
Betty Swartz	Chief Business Officer	no data	no data	no data

2.3yrs

Average Tenure

54yo

Average Age

Experienced Management: 0ET's management team is considered experienced (2.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Sheldon Koenig	President	3yrs	US$2.97m	0.087% $ 323.6k
Nicole Vitullo	Lead Independent Director	16.1yrs	US$94.78k	0.017% $ 62.6k
Alan Fuhrman	Independent Non-Employee Director	4.2yrs	US$104.78k	0.013% $ 49.8k
Antonio Gotto	Independent Director	10.3yrs	US$82.28k	0.012% $ 46.2k
Jay Shepard	Independent Director	6yrs	US$97.28k	0.012% $ 46.2k
Stephen Rocamboli	Independent Director	2.1yrs	US$94.78k	0.0043% $ 16.0k
J. Carroll	Independent Chairperson	1.9yrs	US$117.28k	0.019% $ 71.9k
Peter Libby	Member of Scientific Advisory Board	1.8yrs	no data	no data
Seth H. Fischer	Independent Director	2.6yrs	US$99.78k	0% $ 0
Tracy Woody	Independent Director	5yrs	US$91.97k	0.015% $ 56.0k
Erin Bohula	Member of Scientific Advisory Board	1.8yrs	no data	no data
Jeffrey Bender	Member of Scientific Advisory Board	1.8yrs	no data	no data

2.8yrs

Average Tenure

66yo

Average Age

Experienced Board: 0ET's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.

Esperion Therapeutics Management

Management criteria checks 2/4

Key information

Recent management updates

Esperion Therapeutics, Inc., Annual General Meeting, May 23, 2024

Esperion Therapeutics, Inc. Appoints Ben Halladay as Chief Financial Officer

High number of new directors

High number of new directors

High number of new directors

Esperion Appoints J. Martin Carroll to Its Board of Directors

Recent updates

First quarter 2024 earnings released: EPS: US$0.36 (vs US$0.79 loss in 1Q 2023)

Esperion Therapeutics, Inc. to Report Q1, 2024 Results on May 07, 2024

Esperion Therapeutics, Inc., Annual General Meeting, May 23, 2024

U.S. FDA Approves Broad New Labels for Esperion’s NEXLETOL® and NEXLIZET® to Prevent Heart Attacks and Cardiovascular Procedures in Both Primary and Secondary Prevention Patients, Regardless of Statin Use

Full year 2023 earnings released: US$2.03 loss per share (vs US$3.52 loss in FY 2022)

Esperion Therapeutics, Inc. to Report Q4, 2023 Results on Feb 27, 2024

New minor risk - Financial position

Esperion Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $85.05 million.

U.S. FDA Updates LDL-C Lowering Indication for Esperion's NEXLETOL®? (bempedoic Acid) Tablet and NEXLIZET®? (bempedOic Acid and ezetimibe) Tablet

New major risk - Shareholder dilution

Partners Announce Transform Trial to Evaluate Personalized Heart Disease Care Strategies At American Heart Association 2023

Third quarter 2023 earnings released: US$0.37 loss per share (vs US$0.81 loss in 3Q 2022)

No longer forecast to breakeven

Esperion Therapeutics, Inc. to Report Q3, 2023 Results on Nov 07, 2023

New minor risk - Market cap size

New major risk - Shareholder dilution

Forecast to breakeven in 2024

Esperion Therapeutics, Inc. to Report Q2, 2023 Results on Aug 01, 2023

Esperion Announces Submission of Application for Expanded Indication with the European Medicines Agency (EMA) for NILEMDO® (bempedoic acid) Tablet and NUSTENDI® (bempedoic acid and ezetimibe) Tablet

Esperion Therapeutics, Inc. Announces the Results from its Pre-Specified, Primary Prevention Clear Outcomes Subgroup Analysis

Forecast breakeven date moved forward to 2024

Esperion Presents Results from New Analysis on Cardiovascular Benefits with Bempedoic Acid Treatment At Endo 2023

Esperion Announces Submission of Supplemental New Drug Applications to U.S. Fda for Nexletol(R) (Bempedoic Acid) Tablet and Nexlizet(R) (Bempedoic Acid and Ezetimibe) Tablet

Forecast breakeven date pushed back to 2025

Forecast breakeven date pushed back to 2025

First quarter 2023 earnings released: US$0.79 loss per share (vs US$0.93 loss in 1Q 2022)

Full year 2022 earnings released: US$3.52 loss per share (vs US$9.31 loss in FY 2021)

Esperion Therapeutics, Inc. to Report Q4, 2022 Results on Feb 21, 2023

Esperion Therapeutics, Inc. Provides Earnings Guidance for the Fourth Quarter of 2022

Esperion Therapeutics, Inc. Announces CLEAR Outcomes Accepted as Late-Breaking Clinical Trial at ACC.23 Annual Scientific Session & Expo together with the World Congress of Cardiology

Esperion Therapeutics, Inc. Announces CLEAR Cardiovascular Outcomes Trial of NEXLETOL® (bempedoic acid) Meets Primary Endpoint

Esperion Therapeutics, Inc. Appoints Ben Halladay as Chief Financial Officer

High number of new directors

Third quarter 2022 earnings released: US$0.81 loss per share (vs US$2.62 loss in 3Q 2021)

Esperion Therapeutics, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Esperion Announces Bempedoic Acid NEXLETOL Recommends as Oral Non-Statin Therapy for LDL-Cholesterol Lowering in American College of Cardiology Expert Consensus Decision Pathway

Second quarter 2022 earnings released: US$1.05 loss per share (vs US$1.67 loss in 2Q 2021)

High number of new directors

Esperion Therapeutics, Inc. to Report Q2, 2022 Results on Aug 02, 2022

High number of new directors

Esperion Appoints J. Martin Carroll to Its Board of Directors

High number of new directors

First quarter 2022 earnings released: US$0.93 loss per share (vs US$3.50 loss in 1Q 2021)

High number of new directors

Esperion Therapeutics, Inc. to Report Q1, 2022 Results on May 03, 2022

Esperion Therapeutics, Inc., Annual General Meeting, May 26, 2022

Esperion Therapeutics, Inc. Announces Appointment of Eric Warren, R.Ph. as Chief Commercial Officer

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Esperion Therapeutics, Inc. to Report Q4, 2021 Results on Feb 22, 2022

Forecast breakeven date pushed back to 2024

Forecast breakeven date pushed back to 2024

Esperion Therapeutics, Inc. Provides Earnings Results for the Fourth Quarter of 2021

Third quarter 2021 earnings released: US$2.62 loss per share (vs US$3.07 loss in 3Q 2020)

Forecast to breakeven in 2023

Second quarter 2021 earnings released: US$1.67 loss per share (vs US$4.50 profit in 2Q 2020)

Robbins Geller Rudman & Dowd LLP and Kahn Swick & Foti, LLC Announces Proposed Settlement in the Esperion Therapeutics Securities Settlement

First quarter 2021 earnings released: US$3.50 loss per share (vs US$2.84 loss in 1Q 2020)

Esperion Announces Publication of Rationale and Design of Landmark Clear Cardiovascular Outcomes Trial Evaluating Nexletol (Bempedoic Acid) Tablet in American Heart Journal

Esperion Therapeutics, Inc. Announces the Results of Phase 2 Study Evaluating the Combination of Nexletol® (Bempedoic Acid) 180 Mg Tablet, Ezetimibe 10 Mg and Atorvastatin 20 Mg in Patients with Hypercholesterolemia

Full year 2020 earnings released: US$5.23 loss per share (vs US$3.59 loss in FY 2019)

Revenue misses expectations

Esperion Therapeutics, Inc. to Report Q4, 2020 Results on Feb 23, 2021

New 90-day low: €20.62

Daiichi Sankyo Europe GmbH and Esperion Therapeutics Announces Swissmedic approval for NILEMDO® Tablet and NUSTENDI Tablet

Esperion Therapeutics, Inc. Announces Management Changes

Esperion Announces Results of Pooled Data from Four of Phase 3 Trials Presented at the Virtual American Heart Association Scientific Sessions 2020

Third quarter 2020 earnings released: US$3.07 loss per share

Revenue misses expectations

New 90-day low: €26.12